The alliance will accelerate SMT’s goal towards providing affordable and quality stents for the millions of people suffering from heart disease worldwide
Sahajanand Medical Technologies (SMT), manufacturer of cardiovascular medical stents, has succeeded in bagging prestigious tenders amongst Brazilian hospitals for the distribution of stents. The Indian stent manufacturer won tenders at five hospitals after rigorous examinations and regulatory processes. The alliance will accelerate SMT’s goal towards providing affordable and quality stents for the millions of people suffering from heart disease worldwide.
Tenders won at the five hospitals include, the Army General Hospital, University Hospital Santa Maria, Porto Alegre, Health Secretary for State of Brasilia DF (Government Hospital in Brasilia), the University Hospital Antonio Pedro, Rio de Janeiro and the Hospital of Ministry of Education, Curitiba, Parana, Brazil.
Speaking about the remarkable feat, Rahul Garud, Senior Business Manager – Brazil, International Sales, SMT, said, “It is a matter of great pride that SMT products have been accepted in all the five hospitals. Getting substantial orders from the Army General hospital and Health Secretary for State of Brasilia DF (Government Hospital in Capital of Brazil) after a transparent and very thorough process of evaluation gives great confidence on the quality of SMT products which are backed by Supra family of clinical data published in various index International Journals. SMT has been in Brazil for more than a decade and is now gaining acceptance at the highest level.”
Ganesh Sabat, CEO, SMT said, “We continue to uphold our pledge towards saving millions, this win is a step in that direction and we are delighted with the outcome in delivering the thinnest struts of SMT stents in the South American region. We at SMT believe in long term results which have been proven in its efficacy and safety measures, used across the globe. Focussed on providing patients with the best cardiac care, we continue to work on the advancement on state of the art innovations and improving our portfolio catering to our patients’ healthcare needs.”